Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Steven Treon

Boston, MA Medical Doctor

NPI 1821060138 CMS profile 218059

44 Binney St.., Boston, MA 02115

Open in the dashboard

General payments

$366,328

109 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$1,211,258 paid to institutions, not to them · program years 2019–2025

Through program year 2025, Steven Treon of Boston, MA is reported in the CMS Open Payments database as having received $366,328 across 109 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $1,211,258 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $93,473 11
2024 General $78,753 15
2023 General $27,958 6
2022 General $30,105 15
2021 General $55,391 13
2020 General $16,510 9
2019 General $64,137 40

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Steven Treon
  • Massachusetts median
  • Middle half of Massachusetts
  • National median

In program year 2025, general payments to Steven Treon were reported at $93,473. Among 21,560 Massachusetts profiles paid that year, the median was $147 and the middle half received between $45 and $552.

Show as a table
Year Steven Treon Massachusetts median Middle half National median
2019 $64,137 $133 $40–$617 $163
2020 $16,510 $105 $32–$540 $114
2021 $55,391 $124 $35–$544 $132
2022 $30,105 $126 $40–$510 $149
2023 $27,958 $144 $47–$542 $160
2024 $78,753 $144 $45–$560 $164
2025 $93,473 $147 $45–$552 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. GlaxoSmithKline, LLC. $196,363 20 payments
  2. E.R. Squibb & Sons, L.L.C. $33,075 6 payments
  3. BeiGene Switzerland GmbH $28,826 12 payments
  4. Pharmacyclics LLC, An AbbVie Company $24,973 30 payments
  5. BeiGene USA, Inc. $17,993 6 payments
  6. Janssen Global Services, LLC $13,960 2 payments
  7. Celgene Corporation $9,986 3 payments
  8. Janssen Biotech, Inc. $9,054 13 payments
  9. BeiGene, Ltd. $8,166 4 payments
  10. BeiGene (Suzhou) Co., Ltd. $6,500 2 payments
  11. Other $17,433 11 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $359,938 62 payments
  2. Travel and Lodging $2,319 9 payments
  3. Food and Beverage $2,071 37 payments
  4. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $2,000 1 payment
Products named General payments · program years 2019–2025
  1. BRUKINSA $49,794 19 payments
  2. IMBRUVICA Oncology $22,581 9 payments
  3. Imbruvica Oncology $15,623 27 payments
  4. DARZALEX $13,431 8 payments
  5. IMBRUVICA Oncology $9,350 3 payments
  6. SARCLISA $145 2 payments
  7. TECVAYLI Oncology $97 1 payment
  8. CARVYKTI $97 1 payment
  9. TALVEY $9 1 payment
  10. TECVAYLI Oncology $9 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

109 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record